December 9-11, 2025 | Boston, MA

www.covalent-drug-discovery.com

REGISTER BY FRIDAY, OCTOBER 10 TO SAVE UP TO $633

3rd Annual

Covalent Drug Discovery & Development Summit

Unlocking Holy-Grail Targets with Novel Covalent Therapies

Optimizing Selectivity, Reactivity & Tolerability to Develop Safe, Potent & Clinically Successful Covalent Drugs for Oncology, Immunology & Beyond

Expert Speakers Include:

Brian Cook
Vice President & Head Early Discovery Chemistry
Vividion Therapeutics

Markus Schirle
Executive Director
Novartis

Daniel Nomura
Professor
University of California at Berkeley

Jacob Stuckey
Vice President, Biochemistry & Chemical Biology
Flare Therapeutics

Paola Castaldi
Senior Vice President, Head of Platform & Chemical Biology
Matchpoint Therapeutics

Brendan Hilbert
Director, Protein & Structural Biology
Antares Therapeutics

Proud to Partner With:

Promega

momentum BIOTECHNOLOGIES

+1 617 455 4188 info@hansonwade.com
www.covalent-drug-discovery.com The UnDruggable Series
hansonwade

Welcome to the 3rd Covalent Drug Discovery & Development Summit

3rd Annual Covalent Drug Discovery & Development Summit
December 9-11, 2025 | Boston, MA

With the excitement of **MOMA Therapeutics** **dosing their first patient** with a covalent Werner helicase inhibitor, and **Novartis** partnering with covalent pioneer **Matchpoint Therapeutics** in a **$60 million deal**, the potential of covalent therapies has never been greater.

The **3rd Covalent Drug Discovery & Development Summit** returns as the premier industry forum for experts to accelerate the discovery, translation and development of covalent drugs - driving the next wave of first- and best-in-class therapeutics against previously undruggable targets.

Uniting covalent drug leaders from the likes of **Frontier Medicines, Vividion Therapeutics, Bayer, Matchpoint Therapeutics** and **Pfizer**, this three day deep-dive will explore:

- Optimizing warhead selectivity, reactivity and durability to ensure the development of tolerable, potent covalent therapies
- Targeting non-cysteine residues and hard-to-drug proteins including transcription factors to expand the druggable proteome
- Elucidating PK/PD relationships and understanding ADME and target engagement to inform dosing and streamline clinical development
- Innovating advanced screening technologies and lead optimization strategies to rationally triage hits and progress covalent candidates efficiently

This is your unique opportunity to join **80+ leaders** in **medicinal chemistry**, **biochemistry**, **structural biology** and **translation** to uncover insights on overcoming key challenges in warhead design, lead optimization and preclinical to clinical development, ensuring your pipeline is de-risked to reach patients in need.

What's On in 2025?

80+ Attendees

23+ Speakers

8+ Hours of Networking

2 Interactive Workshops

1 Scientific Poster Session

Key Benefits of Attending

Expand the druggable proteome and target previously 'undruggable' proteins including transcription factors and splicing machinery to unlock treatment options for diseases with unmet medical need. Featuring data from **Talus Bio** and **BridGene Biosciences**

Achieve balanced selectivity and reactivity of covalent warheads through strategic lead optimization and drug design to ensure the development of tolerable, durable and potent therapies. Strategies from **Alterome Therapeutics** and **AstraZeneca**

Discover the unique therapeutic potential of covalency across a diverse range of modalities, including covalent activators and radiopharmaceuticals, enabling breadth of therapeutic application. With case studies from **Actithera** and **Dana Farber Cancer Institute**

Strategize clinical development protocols with confidence by accurately elucidating PK/PD relationships, characterizing ADME and measuring target engagement to inform dosing. Insight from **Novartis** and **Frontier Medicines**

Unleash the next wave of best-in-class covalent therapies with advanced screening technologies, covalent libraries, chemoproteomics platforms and computational modelling. With learnings from **UC Berkeley** and **Vividion Therapeutics**

+1 617 455 4188 info@hansonwade.com
www.covalent-drug-discovery.com The UnDruggable Series
hansonwade

What's New For 2025?

3rd Annual Covalent Drug Discovery & Development Summit
December 9-11, 2025 | Boston, MA

Key Sessions Not to Be Missed

1 Reimagining Druggability using Chemoproteomic Platforms

Daniel Nomura, Professor, **University of California at Berkeley**

LEADING KOL

2 Structural Biology & Computational Challenges in Covalent Targeting of Cryptic Pockets

Brendan Hilbert, Director, Protein & Structural Biology, **Antares Therapeutics**

3 Lysine-Targeted Covalent Probes with Residence-Time-Driven Selectivity

Tangpo Yang, Principal Scientist, **Pfizer**

4 Complementary Strategies for Covalent Hit Finding & Characterization

Markus Schirle, Executive Director, **Novartis**

5 Round Table: Investigating the Feasibility of Targeting Non-Cysteine Residues & Developing Rational Strategies to Drug New Targets

Paramita Deria, Principal Scientist, **Bayer**

New Companies for 2025 Include

matchpoint THERAPEUTICS | Alterome THERAPEUTICS | AstraZeneca | jnana Therapeutics | FRONTIER MEDICINES

FLARE THERAPEUTICS | talusbio | vividion THERAPEUTICS | Actithera | Revolution Medicines

Showcase Your Scientific Poster

Contribute to the conversation and share your cutting-edge research with the covalent drug development community to showcase your breakthrough discoveries to a vast audience of experts.

Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

+1 617 455 4188 info@hansonwade.com
www.covalent-drug-discovery.com The UnDruggable Series

hansonwade

Your Expert Speakers

Andreas Goutopoulos
Chief Executive Officer
Actithera

Brian Cook
Vice President & Head
Early Discovery Chemistry
Vividion Therapeutics

Brendan Hilbert
Director, Protein &
Structural Biology
Antares Therapeutics

Chris Haggard
Chief Technology Officer
Axiom Therapeutics

Daniele Canzani
Senior Scientist II
Talus Bio

Daniel Nomura
Professor
University of California
at Berkeley

Fiona Pachl
Associate Principal
Scientist
AstraZeneca

Ivan Cornella-Taracido
Chief Scientific Officer
Covant Therapeutics

Jianwe (John) Che
Director of Computational
Chemistry Core
Dana Farber Cancer
Institute

Jacob Stuckey
Vice President,
Biochemistry & Chemical
Biology
Flare Therapeutics

Paola Castaldi
Senior Vice President,
Head of Platform &
Chemical Biology
Matchpoint Therapeutics

Lata Jayaraman
Senior Vice President
& Head of Oncology &
Inflammatory Disease
Research
Frontier Medicines

Laura D'Agostino
Vice President, Chemistry
Monimoi Therapeutics

Markus Schirle
Executive Director
Novartis

Matt Labenski
Senior Director,
Proteomics & Chemical
Biology
Jnana Therapeutics

Ning Deng
Director, IMTAC Discovery
BridGene Biosciences

Paramita Deria
Discovery Chemistry
Bayer

Sarah McFann
Principal Scientist
Novartis

Sean Toenjes
Executive Director,
Chemistry & Innovation
Aethon Therapeutics

Sujata Chakraborty
Principal Scientist
Revolution Medicines

Tim Wang
Associate Director,
Discovery Biology
Alterome Therapeutics

Tangpo Yang
Principal Scientist
Pfizer

Uthpala Seneviratne
Associate Principal
Scientist
AstraZeneca

Pre-Conference Workshop Day
Tuesday, December 9, 2025

Check In & Light Breakfast — 8.00

Workshop A — 9.00

Designing the 'Holy-Grail' Warhead to Optimize Selectivity, Reactivity, Affinity & Clearance to Facilitate Development of Efficacious, Safe Covalent Drugs

Maintaining the perfect balance between selectivity and reactivity is key to ensuring covalent therapies are safe and efficacious, but achieving this harmony is challenging.

This workshop will cover:

- Balancing warhead reactivity, selectivity, stability and non-covalent interactions to enable successful binding with cysteine and non-cysteine residues and develop potent, tolerable covalent drugs
- Addressing metabolic challenges by optimizing warhead structure to improve PKPD properties and achieve effective affinity and clearance rates whilst limiting risk of immunogenicity
- Utilizing proteomics, activity based and clickable probes, crystallography, molecular dynamics, biochemical and biophysical methods to measure characteristics of warheads and facilitate ongoing optimization

Workshop Leaders

Brian Cook
Vice President & Head of Early Discovery Chemistry
Vividion Therapeutics
NEW COMPANY

Laura D'Agostino
Vice President, Chemistry
Monimoi Therapeutics
NEW COMPANY

Lunch — 12.00

Workshop B — 1.00

Elucidating Covalent PKPD Relationships & Developing Robust Models to Understand Clearance & Inform Dosing Strategy

To progress covalent therapies through the pipeline to patients, appropriate dosing regimens must be determined to ensure safety and therapeutic response. Understanding PKPD and ADME properties is vital.

This workshop will cover:

- Accurately measuring covalent drug and protein half-life, clearance and target occupancy in a non-equilibrium setting across a range of tissues to elucidate PKPD relationships
- Determining the significance of the interaction between PK, PD, KI, Kinact, target engagement and efficacy, and translating these insights from preclinical models to humans
- Optimizing dosing with in-depth insights into PKPD and ADME and in vitro, in vivo and in silico modelling data, as well as predictive AI, to inform clinical strategy

Workshop Leaders

Sarah McFann
Principal Scientist
Novartis

Lata Jayaraman
Senior Vice President & Head of Oncology & inflammatory Disease Research
Frontier Medicines
NEW COMPANY

End of Pre-Conference Workshop Day — 4.00

Conference Day One
Wednesday, December 10, 2025

7.30 Check In & Light Breakfast

Laura D'Agostino
Vice President, Chemistry
Monimoi Therapeutics

8.20 **Chair's Opening Remarks**

Targeting Previously Undruggable Proteins with Rational Target Selection to Expand the Potential of Covalent Therapies

Lata Jayaraman
Senior Vice President & Head of Oncology & inflammatory Disease Research
Frontier Medicines
NEW COMPANY

8.30 **Extending the Scope of Covalent Drugs to Transcription Factors & Hard to Drug Proteins**

- Defining what makes a good target considering half life, non-covalent secondary interactions and ligandability
- Exploiting chemoproteomics to understand and build selectivity across the proteome
- Strategies to reach previously undruggable targets, such as transcription factors, with covalent modalities

Brendan Hilbert
Director, Protein & Structural Biology
Antares Therapeutics
NEW COMPANY

9.00 **Structural Biology & Computational Challenges in Covalent Targeting of Cryptic Pockets**

- Leveraging protein engineering to enable crystallography for transcription factors
- Overcoming structural biology challenges due to shallow, dynamic pockets
- Enabling covalent small molecule computational design

Paola Castaldi
Senior Vice President, Head of Platform & Chemical Biology
Matchpoint Therapeutics
NEW COMPANY

9.30 **Identification of Functional Covalent Hits with Novel Mechanisms of Action for Hard-to-Drug Targets**

- Drugging elusive targets with high affinity, selectivity and tolerability
- Strategies for target selection and warhead tuning to facilitate selective, potent binding

Daniele Canzani
Senior Scientist II
Talus Bio
NEW COMPANY

10.00 **Unlocking the Regulome for Covalent Drug Discovery using a High-Throughput Proteomics Platform**

- We developed regulome profiling, a platform to measure protein-chromatin binding activity of transcription factors and other chromatin-associated proteins from native cell contexts
- Protein-chromatin binding measurements are validated using tool compounds and proteins, such as MEN1
- Preliminary data from a covalent discovery program demonstrates androgen receptor and a splice variant can be reduced in prostate cancer by targeting the splicing factor NONO

10.30 **Morning Break & Speed Networking**
This is your opportunity to connect and establish meaningful industry relationships with other experts pioneering covalent therapeutics.

Expanding the Druggable Proteome & Targeting Non-Cysteine Residues with Innovative Tools & Warhead Design to Expand Covalency Across More Indications

Jacob Stuckey
Vice President, Biochemistry & Chemical Biology
Flare Therapeutics
NEW COMPANY

11.30 **Insights into Covalent Drug Discovery from FX-909**

- FX-909 is a potent and selective inverse agonist of PPARG currently being explored in muscle-invasive luminal urothelial cancer
- FX-909's selectivity and *in vivo* properties are derived from the "context-dependent reactivity" exhibited by its unique warhead
- Mechanistic investigations into covalent capture of PPARG were critical for the design and discovery of FX-909 and have also revealed insights into the physical basis of its "context-dependence"

Tangpo Yang
Principal Scientist
Pfizer

12.00 **Lysine-Targeted Covalent Probes with Residence-Time-Driven Selectivity**

- Developing lysine-reactive kinase probes that reversibly engage over 200 cellular kinases, enabling broad profiling
- Engineering a salicylaldehyde-based probe that achieves residence-time-driven selectivity in cells and *in vivo*
- Demonstrated *in vivo* target engagement of PF-06873600 using the salicylaldehyde probe, highlighting translational potential

Conference Day One
Wednesday, December 10, 2025

12.30 **Round Table: Investigating the Feasibility of Targeting Non-Cysteine Residues & Developing Rational Strategies to Drug New Target**

Paramita Deria
Principal Scientist
Bayer

- Evaluating the suitably of non-cysteine residues for covalent targeting to assess feasibility of drugging novel proteins
- Exploring the technological advancements required to effectively identify and target alternative amino acids
- Optimizing warhead selectivity and potency to enable precise targeting whilst mitigating against off-target activity

1.00 **Lunch & Networking**

Optimizing Hit ID & Screening Capabilities with Chemoproteomics, Covalent Libraries & Computational Models to Identify Highly Promising Compounds

2.00 **IMTAC™: A Chemoproteomic Platform for Covalent Ligand Discovery to Unlock Investigational Targets**

Ning Deng
Director, IMTAC Discovery
BridGene Biosciences
NEW COMPANY

- Leveraging covalent small-molecule libraries to rapidly identify diverse and hard-to-drug targets
- Live-cell screening under physiological conditions captures native protein conformations and complex cellular dynamics and enhances translational relevance by mimicking *in vivo* target environments
- Key lessons learned and challenges overcome

2.30 **Complementary Strategies for Covalent Hit Finding & Characterization**

Markus Schirle
Executive Director
Novartis

- Strategic application of labelling- vs. function-first approaches for covalent hit finding *in vitro* and in cells
- Chemoproteomics applications for hit characterization and determination of novel ligandable sites on targets of interest
- Library considerations for covalent hit finding at Novartis

3.00 **RAPID – Photoaffinity-Based High-Throughput Ligand Discovery in Cells**

Matt Labenski
Senior Director, Proteomics & Chemical Biology
Jnana Therapeutics
NEW COMPANY

- Pivoting away from mass spec in favor of building a high-throughput chemotherapeutics hit identification platform
- Discovery of first-in-class inhibitors of a genetically validated target for the treatment of PKU Discovery of the first inhibitors for transcription factor IRF3
- Evolving the platform to work with other covalent warheads

3.30 **Afternoon Break & Poster Session**
Take this opportunity to showcase your latest covalent strategies with your peers and understand what other experts are working on. Please visit the website for T&Cs of submitting a poster.

Applying Unique Proteomics Insights & Adopting Computational Modelling to Derisk Pipelines & Streamline Translation from Bench to Bedside

4.30 **Developing a Proteomics Toolkit for the Characterization of Covalent Drug Molecules**

Fiona Pachl
Associate Principal Scientist
AstraZeneca
NEW COMPANY

- Pivoting away from mass spec in favor of building a high-throughput chemoproteomics hit identification platform
- Discovery of first-in-class inhibitors of a genetically validated target to treat PKU
- Discovery of the first inhibitors for transcription factor IRF3
- Evolving the platform to work with other covalent warheads

5.00 **Computational & Machine Learning Approaches to Covalent Therapeutic Discovery**

Chris Haggard
Chief Technology Officer
Axiom Therapeutics
NEW COMPANY

- How can computational simulation and machine learning accelerate the discovery of potent and selective covalent therapeutics?
- What are the limits of current approaches and which emerging techniques are showing promise?
- How can new simulation methods reveal covalent binding kinetics and guide molecular design?

5.30 **End of Conference Day One**

Conference Day Two
Thursday December 11, 2025

8.00 Check In & Light Breakfast

Laura D'Agostino
Vice President, Chemistry
Monimoi Therapeutics

8.50 **Chair's Opening Remarks**

Transforming Hit to Lead Optimization with Strategic Hit Triaging & Warhead Modification to Develop Sufficiently Potent & Selective Covalent Drugs

Uthpala Seneviratne
Associate Principal Scientist
AstraZeneca
NEW COMPANY

9.00 **Increasing the Success of Developing Robust Clinical Candidates through Strategic Starting Points & Rational Hit Progression**

- Defining what makes a good starting point and differentiating between a strong screening and lead compound
- Strategies for transitioning from a successful hit to a sufficiently potent, cell active drug-like molecule
- Understanding non-covalent affinity with biophysical and biochemical techniques to triage hits with highest likelihood of translating into durable, tolerable therapies

Daniel Nomura
Professor
University of California at Berkeley
LEADING KOL

9.30 **Reimagining Druggability Using Chemoproteomic Platforms**

- Covalent chemoproteomic approaches for drugging undruggable targets such as transcription factors
- Covalent approaches to expand upon targeted protein degradation platforms
- Covalent approaches to develop new induced proximity-based therapeutic modalities beyond degradation

Sujata Chakraborty
Senior Scientist
Revolution Medicines
NEW COMPANY

10.00 **Discovery of RMC-9805, an Oral, RAS(ON)G12D-Selective Covalent Tri-Complex Inhibitor**

- The investigational agent RMC-9805 is a first-in-class, orally bioavailable, mutant selective covalent inhibitor of RASG12D(ON) that forms a tri-complex between the abundant intracellular chaperone cyclophilin A (CypA) and the "ON" state of RASG12D, enabling selective covalent engagement of Asp-12 and disrupting downstream RAS signaling by steric occlusion of effector binding
- RMC-9805 drove selective and persistent covalent modification of KRASG12D in human cancer cell lines *in vitro*, leading to deep and durable suppression of RAS pathway activity, inhibition of cell proliferation, and apoptosis
- RMC-9805 monotherapy induced tumor regressions at well-tolerated doses in a majority of preclinical PDAC and NSCLC models harboring KRASG12D

Tim Wang
Associate Director, Discovery Biology
Alterome Therapeutics
NEW COMPANY

Ivan Cornella-Taracido
Chief Scientific Officer
Covant Therapeutics

10.30 **Fireside Chat: Improving Lead Optimization to Advance Hits into Potent, Tolerable & Clinically Successful Covalent Therapies**

- Strategizing for successful hit to lead optimization by overcoming bottlenecks in clearance, target occupancy and selectivity
- Adapting lead optimization as compounds move through the development pipeline from in vitro to in vivo models
- Lessons learn from abandoned candidates and emerging trends of which sites are most suitable for therapeutic development

11.00 Morning Break & Networking

Conference Day Two
Thursday December 11, 2025

Streamlining Translation of Covalent Candidates through Smart Drug Development & Accurate Understanding of Dosing Regimens to Bring Therapies to Patients Faster

Brian Cook
Vice President & Head of Early Discovery Chemistry
Vividion Therapeutics
NEW COMPANY

11.45 **A Covalent-First Approach to Identify Novel Drug Targets**

- Building a covalent-first fragment library (design principles)
- Generation of scout ligands/stereoprobes
- Optimization of covalent-first hits/balancing electrophile reactivity
- Evaluation of the types of pockets accessible through this approach

Ivan Cornella-Taracido
Chief Scientific Officer
Covant Therapeutics

12.15 **Round Table: Measuring Target Occupancy, Affinity & Efficacy with Advanced Tools & Models to Guide Warhead Optimization**

- Tools and technologies for measuring target occupancy and assessing the accuracy of occupancy models including PBBK, QSP and SPR
- Debating the application and usefulness of KI / Kinact measurements for kinetic optimization
- Evaluating the relationship between PD, efficacy and target engagement and tuning warheads in response

12.45 **Lunch Break & Networking**

Exploring the Untapped Potential of Covalent Biologics & Non-Inhibitory Covalent Molecules to Treat a Greater Range of Indications & Patients

Andreas Goutopoulos
Chief Executive Officer
Actithera
NEW COMPANY

1.45 **Leveraging Covalency to Achieve Optimal Pharmacokinetic Profiles for Radiotherapeutics**

- Introduction to Radiotherapeutics and why they require a unique pharmacokinetic profile
- Discuss the concept of covalency and how it fits in Radiotherapeutics
- Provide examples of covalency in developing superior Radiotherapeutics – an example from the FAP (fibroblast activation protein) field

Sean Toenjes
Executive Director, Chemistry & Innovation
Aethon Therapeutics
NEW COMPANY

2.15 **Discovery of Bispecific T-Cell Engagers Targeting Covalent Drug-Modified KRASG12C Neoantigens**

- Development of engineered bispecific T-Cell engagers that recognize KRAS covalent inhibitor–modified peptide-MHC complexes with high affinity and specificity
- Companion immunotherapy approach designed to complement KRASG12C inhibitors enabling selective killing of resistant tumor cells *in vitro* and *in vivo*
- Cross-HLA binding and structural insights supporting broad patient coverage and the molecular basis for recognition of hapten-modified targets

Jianwei (John) Che
Director of Computational Chemistry Core
Dana Farber Cancer Institute
LEADING KOL

2.45 **Beyond Inhibitors: Developing Covalent Activators with the Potential to Transform Treatment Options for Patients**

- Exploring covalent activators as an advantageous alternative to covalent inhibitors
- Data to demonstrate the unique benefit of using non-inhibitory covalent compounds in terms of selectivity and potency
- Outlining the future development strategy for covalent activators to enable progression into the clinic

3.15 **End of 3rd Covalent Drug Discovery & Development Summit**

2025 Partners

Exhibition Partner

Promega is committed to excellence in technologies and compound profiling services to assess key processes in Targeted Protein Degradation and Induced Proximity mechanisms. From assessing protein degradation in real time, to understanding compound binding and permeability, to ternary complex formation and more. Our CRIPSR HiBiT content covers hundreds of pre-built targets. Novel software analysis tools allow for the determination of target protein degradation rates, DC50 potency values, recovery profiles and more.

www.promega.co.uk

Exhibition Partner

Momentum Biotechnologies, founded in 2014, is a drug discovery partner providing specialized mass spectrometry technologies to clients worldwide. Through a diverse array of services, including affinity-selection mass spectrometry (ASMS), covalent binding assays, proteomics / chemoproteomics, and small-molecule analysis, Momentum helps clients identify, validate, and characterize therapeutic leads, accelerating critical drug discovery efforts. In early 2025, Momentum expanded to Europe, where it operates as OmicScouts, a Momentum Biotechnologies Company.

www.momentum.bio

> "I'm looking forward to discussing with other experts how machine learning, mechanistic modeling, and preclinical safety, efficacy, and PK studies can best be used to inform lead optimization and choice of dosing regimen for covalent modalities"
>
> Principal Scientist, **Novartis**

Get Involved

Hannah Martin
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

3rd Annual Covalent Drug Discovery & Development Summit
December 9-11, 2025 | Boston, MA

Are you committed to supporting the development of highly efficacious, durable, and tolerable covalent therapies across a range of modalities?

The **3rd Covalent Drug Discovery & Development Summit** is your unique opportunity to position yourself amongst the most innovative players in covalent drug development to showcase your solutions and capabilities.

Biopharma is increasingly looking to covalency to overcome challenges in therapeutic potency and toxicity, yet challenges in warhead design, screening capabilities and assay development are hindering development.

From **covalent libraries** to **chemoproteomics** expertise, **computational modelling** to **DMPK** and **toxicity testing**, the industry leaders gathering at this forum are looking for solutions to drive the selectivity, reactivity and safety of their covalent candidates– **can you help?**

Partnership Benefits Include:

Position yourself as the leading covalent expert

Connect with a targeted audience of decision makers dedicated to developing covalent therapeutics, looking for support to optimize this promising chemistry

Keep your finger on the pulse in covalency

Gain first-hand insight directly from drug discovery leaders to better understand the challenges of developing covalent molecules so you can efficiently deliver solutions

Build vital connections with the covalent community

Enjoy 7+ hours of dedicated networking time to unite with the biggest names in covalency, pioneering start-ups and academic innovators during the poster session and speed-networking breaks

Maximize your brand visibility and credibility

Take advantage of branding opportunities and share your newest data on covalent screening techniques or balancing warhead reactivity, creating a lasting impression of your capabilities

Seniority of Attendees



- 31% C-Level Executive & President
- 37% Director & Head
- 20% Scientist
- 5% Professor
- 3% Manager
- 4% Other

Type of Companies Attending



*Statistics taken from the 2nd Covalent Drug Discovery & Development Summit

Get Involved

Hannah Martin
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.covalent-drug-discovery.com/take-part/register/

Tel: +1 617 455 4188

Email: info@hansonwade.com

Optimize end-to-end pipeline development, with advanced screening techniques, improved hit to lead optimization and strategic clinical protocols to maximize efficiency of covalent drug development

Expand the potential of covalency across more modalities, targets and indications than ever before to unlock the druggable proteome and bring safe, efficacious covalent drugs to patients in need

Connect with fellow covalent pioneers to keep your finger on the pulse of the latest clinical updates and emerging chemistries, and uncover new data and R&D strategies to take home to your own pipeline

Drug Developer Pricing *	Register & Pay by Friday, October 10	On the Door Price
Conference + 2 Workshops	$3,564 **(save $633)**	$4,197
Conference + 1 Workshop	$3,098 **(save $500)**	$3,598
Conference Only	$2,632 **(save $367)**	$2,999
Academic Pricing **	**Register & Pay by Friday, October 10**	**On the Door Price**
Conference + 2 Workshops	$2,964 **(save $633)**	$3,597
Conference + 1 Workshop	$2,598 **(save $500)**	$3,098
Conference Only	$2,232 **(save $367)**	$2,599
Solution & Service Provider Pricing	**Register & Pay by Friday, October 10**	**On the Door Price**
Conference + 2 Workshops	$4,464 **(save $633)**	$5,097
Conference + 1 Workshop	$3,898 **(save $500)**	$4,398
Conference Only	$3,332 **(save $367)**	$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Revere Hotel Boston Common
200 Stuart St, Boston, MA 02116, United States
www.reverehotel.com